(24/7 MARKET NEWS) – Chimerix (NASDAQ:CMRX) popped after announcing that it signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), in the HHS’s Administration for Strategic Preparedness and Response (ASPR), for the delivery of up to 1.7 million treatment courses of tablet and suspension formulations of TEMBEXA(R) to the U.S. government.
After hitting a high of $2.68, following the news, Chimerix is at $2.47, 31 cents higher (+14.35%), on nearly 30 million shares.
The 10-year contract, 75A50122C00047, includes an initial product procurement of 319,000 treatment courses for approximately $115 million and contains options for future procurements, valued at approximately $551 million in total if BARDA elects to exercise all options, and post-marketing activities budget of approximately $13 million, for a total potential contract value of up to $680 million.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
